Drugs / ABP 938
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | US (FDA) | — | — | 2023-10-31 | “The FDA accepted the Biologics License Application for ABP 938, an investigational biosimilar to EYLEA ® (aflibercept).” amgen.com ↗ |
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07614776 | May 2026 → Jul 2027 expected | wet macular degeneration | Amgen | Recruiting | No outcome recorded |
| Phase 3 | NCT05704725 | Jan → Feb 2023 | retinal vascular disorder | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT04270747 | Jun 2020 → Jul 2022 | wet macular degeneration | Amgen | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABP 938 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05704725 ↗ |
| Route | Intravitreal | “ABP 938 2 mg (0.05 mL) IVT injection every 4 weeks” NCT04270747 ↗ |